Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Corvus Pharmaceuticals, Inc is a biotechnology business based in the US. Corvus Pharmaceuticals shares (CRVS) are listed on the NASDAQ and all prices are listed in US Dollars. Corvus Pharmaceuticals employs 52 staff and has a market cap (total outstanding shares value) of USD$113.5 million.
|52-week range||USD$1.01 - USD$6.88|
|50-day moving average||USD$3.9894|
|200-day moving average||USD$3.5609|
|Wall St. target price||USD$9.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.559|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-35.11%|
|Return on equity TTM||-64.91%|
|Market capitalisation||USD$113.5 million|
TTM: trailing 12 months
There are currently 1.4 million Corvus Pharmaceuticals shares held short by investors – that's known as Corvus Pharmaceuticals's "short interest". This figure is 14.3% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting Corvus Pharmaceuticals shares can be evaluated.
Corvus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corvus Pharmaceuticals shares currently shorted divided by the average quantity of Corvus Pharmaceuticals shares traded daily (recently around 333042.7184466). Corvus Pharmaceuticals's SIR currently stands at 4.12. In other words for every 100,000 Corvus Pharmaceuticals shares traded daily on the market, roughly 4120 shares are currently held short.
However Corvus Pharmaceuticals's short interest can also be evaluated against the total number of Corvus Pharmaceuticals shares, or, against the total number of tradable Corvus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corvus Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Corvus Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.1016% of the tradable shares (for every 100,000 tradable Corvus Pharmaceuticals shares, roughly 102 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Corvus Pharmaceuticals.
Find out more about how you can short Corvus Pharmaceuticals stock.
We're not expecting Corvus Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Corvus Pharmaceuticals's shares have ranged in value from as little as $1.01 up to $6.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corvus Pharmaceuticals's is 2.0339. This would suggest that Corvus Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.